SAT0254 Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from select-next
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1202
Abstract: Background: Upadacitinib (UPA), a selective JAK-1 inhibitor, has demonstrated efficacy in active RA among patients with an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD-IR).1 To understand treatment effectiveness from the patients’ perspective we… read more here.
Keywords: employee abbvie; abbvie; shareholder abbvie; employee ... See more keywords
SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL)
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1254
Abstract: Background Patient reported outcomes (PROs) were studied in patients with active rheumatoid arthritis (RA) who had an inadequate response to biologic disease modifying anti-rheumatic drugs (bDMARD-IR) in a trial of upadacitinib (UPA), a selective JAK-1… read more here.
Keywords: employee abbvie; abbvie; shareholder abbvie; employee ... See more keywords